As Castellani Takes PhRMA's Helm, Where Does Personalized Medicine Advocacy Stand? | GenomeWeb

Originally published Aug. 10.

By Turna Ray

The resignation of Billy Tauzin as the head of the Pharmaceutical Research and Manufacturers of America may be welcomed by those in the drug industry who feel he failed to represent the interests of drugmakers during healthcare reform. However, the former congressman from Louisiana and outspoken cancer survivor will certainly be missed by personalized medicine advocates for his vocal support of their cause.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.